In last trading session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) saw 0.41 million shares changing hands with its beta currently measuring -0.67. Company’s recent per share price level of $5.42 trading at -$0.32 or -5.56% at ring of the bell on the day assigns it a market valuation of $371.59M. That closing price of AMLX’s stock is at a discount of -268.08% from its 52-week high price of $19.95 and is indicating a premium of 70.85% from its 52-week low price of $1.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.53 million shares which gives us an average trading volume of 1.45 million if we extend that period to 3-months.
For Amylyx Pharmaceuticals Inc (AMLX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.17. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.6 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Upright in the red during last session for losing -5.56%, in the last five days AMLX remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $5.42 price level, adding 7.35% to its value on the day. Amylyx Pharmaceuticals Inc’s shares saw a change of -63.17% in year-to-date performance and have moved 4.45% in past 5-day. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) showed a performance of 2.86% in past 30-days. Number of shares sold short was 1.53 million shares which calculate 0.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 9.67% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 11. It follows that stock’s current price would jump 44.65% in reaching the projected high whereas dropping to the targeted low would mean a gain of 44.65% for stock’s current value.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
Statistics highlight that Amylyx Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 215.17% of value to its shares in past 6 months, showing an annual growth rate of -712.86% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -76.88% from the last financial year’s standing.
Company posted 108.45M and 88.64M of sales in current and next quarters respectively a year earlier.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Insiders are in possession of 14.32% of company’s total shares while institution are holding 82.47 percent of that, with stock having share float percentage of 96.25%. Investors also watch the number of corporate investors in a company very closely, which is 82.47% institutions for Amylyx Pharmaceuticals Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at AMLX for having 4.22 million shares of worth $8.03 million. And as of 2024-06-30, it was holding 6.2251 of the company’s outstanding shares.
The second largest institutional holder is AQR CAPITAL MANAGEMENT LLC, which was holding about 3.34 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.9237 of outstanding shares, having a total worth of $6.35 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 1.81 shares of worth $10.03 million or 2.64% of the total outstanding shares. The later fund manager was in possession of 600.39 shares on Jun 30, 2024 , making its stake of worth around $3.33 million in the company or a holder of 0.88% of company’s stock.
